DelveInsight’s, “Hypertension Pipeline Insight, 2026” report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in Hypertension pipeline landscape. It covers the Hypertension pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hypertension pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead in understanding the Hypertension Treatment Landscape @ https://www.delveinsight.com/sample-request/hypertension-pipeline-insight

Key Takeaways from the Hypertension Pipeline Report

• On June 10, 2026- Merck Sharp & Dohme LLC initiated a Phase 3 study is planned to confirm the efficacy and safety in Japanese PAH participants. The primary population of this study is Japanese PAH participants with World Health Organization Functional Class (WHO FC) II or III while the study includes PAH participants with WHO FC I or IV as other populations. There are no hypotheses for this study.
• On June 10, 2026- GB002 Inc. announced a study will evaluate the long-term safety, tolerability and efficacy of orally inhaled seralutinib in subjects who have completed a previous seralutinib study.
• On June 10, 2026- Insmed Incorporated initiated a phase 3 study is to evaluate the effect of 24-weeks of once daily treatment with TPIP compared with placebo on exercise capacity in adults with PAH.
• On June 05, 2026- Actelion conducted a phase 2 study to confirm the selexipag starting dose(s), selected based on pharmacokinetic (PK) extrapolation from adults, that leads to similar exposure as adults doses in children from greater than or equal to (>=) 2 to less than (˂) 18 years of age with Pulmonary Arterial Hypertension (PAH), by investigating the PK of selexipag and its active metabolite ACT-333679 in this population.
• DelveInsight’s Hypertension pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Hypertension treatment.
• The leading Hypertension Companies such as Gossamer Bio, Addpharma Inc., Insmed Incorporated, Alnylam Pharmaceuticals, 35Pharma Inc, Pfizer, Pharmosa Biopharm Inc., Guangzhou Magpie Pharmaceuticals Co., Ltd., Suzhou Sanegene Bio Inc., JW Pharmaceutical and others.
• Promising Hypertension Pipeline Therapies such as Ramipril and hydrochlorothiazide, Liraglutide , Nebivolol, Metoprolol XL, Aliskiren and HCTZ, Bunazosin, Doxazosin, Valsartin, losartan potassium and others.

Discover groundbreaking developments in Hypertension Therapies! @ Hypertension Ongoing Clinical Trials Assessment

The Hypertension Pipeline Report provides a disease overview, pipeline scenario, and therapeutic assessment of the key pipeline therapies in this domain. The Hypertension Pipeline Report also highlights the unmet needs with respect to the Hypertension.

Hypertension Overview

Hypertension, commonly known as high blood pressure, is a chronic medical condition characterized by elevated pressure in the arteries, which can lead to serious health complications if left untreated. It is classified into primary hypertension, which has no identifiable cause and often develops gradually over many years, and secondary hypertension, which results from an underlying condition, such as kidney disease or hormonal disorders.

Hypertension Emerging Drugs Profile

• Seralutinib: Gossamer Bio

Seralutinib, developed by Gossamer Bio, is an inhaled medication designed to treat pulmonary arterial hypertension (PAH). It functions as an antagonist of several receptors, including platelet-derived growth factor receptors (PDGFRα and PDGFRβ), colony-stimulating factor 1 receptor (CSF1R), and c-KIT. This multi-target approach aims to mitigate the inflammatory and proliferative pathways that contribute to pulmonary vascular remodeling associated with PAH. Currently, the drug is in the Phase III stage of its development for the treatment of Pulmonary Arterial Hypertension.

• AD-209: Addpharma Inc.

AD-209 is an investigational drug developed by Addpharma Inc., primarily targeting hypertension. It is part of a broader pipeline that includes various innovative medicines aimed at treating multiple conditions, including hyperlipidemia and diabetes. Currently, the drug is in the Phase III stage of its development for the treatment of Hypertension.

• Zilebesiran: Alnylam Therapeutics

Zilebesiran is an investigational RNA interference (RNAi) therapeutic developed by Alnylam Therapeutics, specifically targeting hypertension. It is designed to inhibit the synthesis of angiotensinogen (AGT), a key precursor in the Renin-Angiotensin-Aldosterone System (RAAS), which plays a crucial role in blood pressure regulation. Zilebesiran works by utilizing RNAi technology to selectively reduce the production of AGT in the liver. This reduction leads to decreased levels of angiotensin II, a potent vasoconstrictor that contributes to elevated blood pressure. By lowering AGT synthesis, zilebesiran aims to achieve sustained reductions in blood pressure over time. Currently, the drug is in the Phase II stage of development to treat Hypertension.

• LAM-001: ORPHAI THERAPEUTICS

LAM-001 is an investigational inhaled formulation of sirolimus (also known as rapamycin) developed by OrphAI Therapeutics. It is designed specifically for the treatment of pulmonary hypertension (PH) and bronchiolitis obliterans syndrome (BOS), conditions that can significantly impact lung function and patient quality of life. Currently, the drug is in the Phase II stage of development to treat Pulmonary Hypertension.

• HS135: 35Pharma Inc.

HS135 is an investigational drug developed by 35Pharma Inc., focusing on the treatment of pulmonary hypertension (PH) and related cardiometabolic diseases. It is a multi-specific receptor ectodomain ligand trap designed to neutralize activins and growth differentiation factors (GDFs), which are validated drivers of these conditions. HS135 functions as a ligand trap that specifically targets and inhibits the activity of activins and GDFs, particularly activin A and GDF-8. By doing so, it aims to rebalance the signaling pathways involved in various pathologies associated with pulmonary hypertension and obesity-related heart failure. Currently, the drug is in the Phase I stage of development to treat Pulmonary Arterial Hypertension.

Uncover critical updates on therapeutic innovations and their potential impact on patients @ Hypertension Unmet Needs

The Hypertension Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Hypertension with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hypertension Treatment.
• Hypertension Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Hypertension Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hypertension market

Hypertension Companies

Gossamer Bio, Addpharma Inc., Insmed Incorporated, Alnylam Pharmaceuticals, 35Pharma Inc, Pfizer, Pharmosa Biopharm Inc., Guangzhou Magpie Pharmaceuticals Co., Ltd., Suzhou Sanegene Bio Inc., JW Pharmaceutical and others.

Hypertension pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Hypertension Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Transform your understanding of the Hypertension Pipeline! @ Hypertension Market Drivers and Barriers, and Future Perspectives

Scope of the Hypertension Pipeline Report

• Coverage- Global
• Hypertension Companies- Gossamer Bio, Addpharma Inc., Insmed Incorporated, Alnylam Pharmaceuticals, 35Pharma Inc, Pfizer, Pharmosa Biopharm Inc., Guangzhou Magpie Pharmaceuticals Co., Ltd., Suzhou Sanegene Bio Inc., JW Pharmaceutical and others.
• Hypertension Pipeline Therapies- Ramipril and hydrochlorothiazide, Liraglutide, Nebivolol, Metoprolol XL, Aliskiren and HCTZ, Bunazosin, Doxazosin, Valsartin, losartan potassium and others.
• Hypertension Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Hypertension Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Access the Full Hypertension Pipeline Analysis Today! @ Hypertension Drugs and Companies

Table of Contents

1. Introduction
2. Executive Summary
3. Hypertension: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Hypertension – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Seralutinib: Gossamer Bio
9. Mid Stage Products (Phase II)
10. Zilebesiran: Alnylam Therapeutics
11. Early Stage Products (Phase I)
12. HS135: 35Pharma Inc.
13. Preclinical and Discovery Stage Products
14. Drug name: Company name
15. Inactive Products
16. Hypertension Key Companies
17. Hypertension Key Products
18. Hypertension- Unmet Needs
19. Hypertension- Market Drivers and Barriers
20. Hypertension- Future Perspectives and Conclusion
21. Hypertension Analyst Views
22. Hypertension Key Companies
23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/hypertension-pipeline-insight